Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

about

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.SOHO State-of-the-Art Update and Next Questions: MPN.

P2860

Q38371628-3B27504F-800C-462F-BD35-804B0D8B82BA Q39321106-188A1220-7029-4667-82DC-6A3A7833ED35 Q49580473-F2BF5C84-96AA-4875-B34F-E8BCAD3DF4F4

P2860

Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

Item

http://www.wikidata.org/entity/Q39041471

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Approach to patients with esse ...... is the evidence for treatment?

@en

Approach to patients with esse ...... is the evidence for treatment?

@nl

type

Item

label

Approach to patients with esse ...... is the evidence for treatment?

@en

Approach to patients with esse ...... is the evidence for treatment?

@nl

prefLabel

Approach to patients with esse ...... is the evidence for treatment?

@en

Approach to patients with esse ...... is the evidence for treatment?

@nl

P1476

Approach to patients with esse ...... is the evidence for treatment?

@en

P2093

Kate J Newberry

http://www.w3.org/2001/XMLSchema#string

Prithviraj Bose

http://www.w3.org/2001/XMLSchema#string

P2860

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera

Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thr

Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

Guideline for investigation and management of adults and children presenting with a thrombocytosis

Long-term use of anagrelide in young patients with essential thrombocythemia.

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin.

P304

352-364

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.14443

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

176

http://www.w3.org/2001/XMLSchema#string

P50

Lorenzo Falchi

Srdan Verstovsek

P577

2016-12-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27984634

http://www.w3.org/2001/XMLSchema#string

Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

about

P2860

P2860

Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698